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Objective: Numerous recent reports have observed a low osteoinductive efﬁcacy property of bone
morphogenetic protein-2 (BMP-2) and disappointing long-term outcomes in clinical cases. An alternative
hypothesis, that these observations are caused by an exaggerated inﬂammatory environment, needs
experimental evidence.
Method: Thirty-seven Sprague Dawley (SD) rats were administrated with Lipopolysaccharide (LPS)
injections and BMP-2/absorbable collagen sponge (ACS) implantation to respectively mimic pre-
operative and post-operative inﬂammatory responses. Blood samples and BMP-2/ACS implants were
analyzed by enzyme-linked immunosorbent assay (ELISA), real-time polymerase chain reaction (PCR),
micro-computed tomography (mCT) and histological examination.
Results: LPS injections and BMP-2/ACS implantation provoked a signiﬁcant elevation of inﬂammatory
cytokines in serum and an obvious inﬁltration of inﬂammatory cells around BMP-2/ACS implants. The
bone volume, mineral content and mineral density of the BMP-2/ACS implants from LPS-injected rats
were signiﬁcantly decreased, indicating that attenuated BMP-2-induced bone mass might be associated
with down-regulated bone formation activity and up-regulated bone resorption activity. Furthermore,
histological examination of the rhBMP-2/ACS implants showed a decreased expression of osteocalcin
(OCN) and an increased number of osteoclasts in LPS-injected rats at 8 weeks; the expression level of
bone turnover markers in serum and BMP-2/ACS implants revealed inhibited osteoblastogenesis activity
and activated osteoclastogenesis activity in LPS-injected rats. Among the top three elevated pro-
inﬂammatory cytokines, tumor necrosis factor-a (TNF-a) and interleukin-1b (IL-1b) showed a suppres-
sive effect on BMP-2-induced osteoblastic differentiation in vitro.
Conclusion: These data indicate that an exaggerated inﬂammatory environment may decrease BMP-2/
ACS-induced bone mass in vivo by suppressing BMP-2-induced osteoblastic differentiation and by
increasing the number or activity of osteoclasts. The negative role of exaggerated inﬂammation deserves
consideration for future clinical use of BMP-2 in inducing bone regeneration.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Q. Li, Department of Plastic
Hospital, Shanghai Jiao Tong
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G.-M. Zou, Shanghai Cancer
an Road, Wenxuan Medicine
u), dr.liqingfeng@shsmu.edu.
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Bone morphogenetic protein-2 (BMP-2) is a powerful differen-
tiation factor that is capable of recruiting stem cells from sur-
rounding muscle, bone marrow, or blood vessels and then inducing
these cells to differentiate into osteoblastic cells to create bone1.
Preclinical and clinical research have also clearly shown the potent
osteoinductive properties of recombinant human bone morpho-
genetic protein-2 (rhBMP-2) in vivo, making it a potential agent fortd. All rights reserved.
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cations2,3. Since 2002, the INFUSE® Bone Graft, which contains
rhBMP-2 at a concentration of 1.5 mg/cc delivered on an absorbable
collagen sponge (ACS), has been approved in the United States for
clinical use in speciﬁc clinical scenarios, including anterior and
lumbar interbody spine fusion, open tibial fractures, sinus aug-
mentations, and alveolar ridge defects4,5. Early studies of BMP-2/
ACS demonstrated its safety proﬁle and relatively signiﬁcant re-
sults at the site of implantation. However, extended clinical use of
BMP-2/ACS has revealed increasing concerns regarding
inﬂammation-related adverse events such as soft-tissue swelling6,7,
seroma8,9, bone resorption10 and particularly the low osteoinduc-
tive efﬁcacy of BMP-2. These complications have resulted in un-
satisfactory long-term outcomes in clinical applications11e13.
The possible causes of low osteoinductive efﬁcacy of BMP-2 and
disappointing long-term outcomes remain unclear. Recently, clin-
ical and experimental investigators have observed exaggerated
inﬂammation responses after BMP-2/ACS implantation14e19. The
effects of inﬂammation on bone regeneration are complex and
biphasic. It is recognized that an initial and proper inﬂammatory
response is required to initiate and guide the subsequent processes
of bone regeneration. In contrast, deﬁcient or excessive inﬂam-
mation can inhibit or delay bone tissue regeneration20,21. Further-
more, the use of anti-inﬂammatory drugs such as bone
morphogenetic protein-binding peptide (BBP)22, triptolide-mi-
celles23, and corticosteroids17,24 was proved to reduce inﬂamma-
tory responses and subsequently enhances the osteoinductive
capacity of BMP-2. These results indicate that the low osteoinduc-
tive efﬁcacy of BMP-2 in vivo may be a result of the exaggerated
inﬂammatory environment. However, only limited works investi-
gated the effects of an inﬂammatory environment on the osteoin-
ductive efﬁcacy of BMP-2. In vitro, our previous study demonstrated
that LPS-induced inﬂammation inhibits BMP-2-induced osteo-
blastic differentiation of bone mesenchymal stem cells (BMSCs)25.
Inﬂammatory cytokines such as TNF-a also have been found to
suppress BMP-2-induced osteoblastogenesis in vitro26,27. However,
the in vivo inﬂammatory environment is more complex than the
in vitro inﬂammation models mimicked by pro-inﬂammatory
cytokine or agonist treatment, and the exact effects of an exag-
gerated inﬂammatory environment on BMP-2-induced bone for-
mation in vivo need support from data.
The goal of the current study was to further characterize an
exaggerated inﬂammatory environment's role on BMP-2/ACS-
induced bone formation. We hypothesized that the exaggerated
inﬂammatory environment would decrease BMP-2/ACS-induced
bone mass. We artiﬁcially mimicked an exaggerated inﬂamma-
tory model using LPS injections and BMP-2/ACS implantation in
rats. Then, we analyzed several bone turnover markers and the
bonemass of the newly formed bone nodules. Finally, we tested the
effects of the major pro-inﬂammatory cytokines on BMP-2-induced
osteoblastic differentiation.
Materials and methods
Experimental design
Thirty-seven 10-week-old male Lewis rats (body weight
267.6 ± 10.8 g, Shanghai Experimental Animal Center, China) were
used in this experiment and were randomly allocated to three
groups: the LPS-injected group (n ¼ 16), the saline-injected group
(n ¼ 16), and the sham-operated group (n ¼ 5). The experimental
protocol is shown in Fig. 1(A and B); 5 mg/kg of LPS (Sigma, USA) or
equal volume of salinewas injected subcutaneously each day over 4
days to mimic a pre-operative inﬂammatory environment, and the
rats then accepted BMP-2/ACS implants on the last day of LPSinjection to mimic a post-operative inﬂammatory environment.
The sham-operated group was taken as controls to evaluate the
inﬂammatory environment. Specimens of BMP-2/ACS implants
were harvested on days 3, 8, 28, and 56 after implantation. The
experimental procedures were approved by our institution's Ani-
mal Research Committee.
Preparation of rhBMP-2/ACS complex
Absorbable type I bovine collagen sponges (ACS, Integra Life
Sciences, USA), which are used as carriers for rhBMP-2, were
tailored in dimensions of 10  10  5 mm. Each sponge was loaded
with 200 mL of solution containing 4 mg of rhBMP-2 (PeproTech,
USA) under sterile conditions. After 1 h at room temperature, the
rhBMP-2/ACS implants were stored overnight in tissue culture
plates at 4C and were implanted the next day.
Animal model of ectopic bone formation
The rats were anesthetized with ketamine hydrochloride
(100 mg/kg, i.m.) and xylazine hydrochloride (5 mg/kg, i.m.). The
surgical sitewas exposed through a sterile drape. Aseptic techniques
were used for all of the surgical procedures. Two 25-mm-long pos-
terior longitudinal incision (1 cm from the midline, and thus 2 cm
from each other) was made to expose the subcutaneous space for
insertionof sponges.Bluntdissectionwasused to create twoseparate
pockets at each incision site. Sixty-four rhBMP-2/ACS implants were
placed into the pockets in 32 rats (each rat received two sponges).
Biochemical assays
Blood serum was collected on days 3 (the ﬁrst day of LPS in-
jection), 2, 0 (before BMP-2/ACS implantation), 2, 4, 7, 10, 13, 16,
and 18. Serum specimens obtained ondays 0 anddays 4 (4 days after
BMP-2/ACS implantation) were used for pro-inﬂammatory and
anti-inﬂammatory cytokines expression proﬁle (including IL-1a, IL-
1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, granulocyte-macro-
phage colony-stimulating factor (GM-CSF), interferon-g, and TNF-a)
analysis using a Bio-Plex Pro™ Rat Cytokine Th1/Th2 Assay kit (Bio-
Rad Laboratories, USA). Then, the levels of the three most elevated
pro-inﬂammatory cytokines, including TNF-a, IL-1b, and IL-6, the
bone turnover markers, including C-terminal fragment of collagen I
(CTX-1), tartrate-resistant acid phosphatase 5b (TRACP-5b), OCN,
and the exogenous BMP-2 in serum were analyzed using enzyme-
linked immunosorbent assay (ELISA) kits (all from R&D, USA) ac-
cording to the manufacturer's instructions. The blood samples from
the sham-operated rats were used to measure the basal levels of
these pro-inﬂammatory and anti-inﬂammatory cytokines.
Histological and histomorphometry
The BMP-2/ACS implants harvested at days 3 and 8 were used
for inﬂammation analysis (n ¼ 6) and the implants harvested at
days 28 and 56 were used for bone mass analysis (n ¼ 10). The
specimens were rinsing in sterile saline and ﬁxed in 4% para-
formaldehyde for 2 days. After rinsing inwater, the specimens were
decalciﬁed in 20% ethylenediaminetetraacetic acid (EDTA) for 30
days and embedded in parafﬁn (for inﬂammation analysis, the
specimens were directly embedded in parafﬁn). Serial sections,
5 mm thick, were prepared at intervals of 80 mm, stained with he-
matoxylin and eosin (H&E), Van Gieson (VG), and tartrate-resistant
acid phosphatase (TRAP) for the evaluation of inﬂammation, bone
structures, and osteoclasts, respectively. For quantitative analysis of
the osteoclasts, TRAP-positive cells were counted under the mi-
croscope at a 40 magniﬁcation in a blinded fashion.
Fig. 1. Experimental protocol of this study. (A) Time course of the experimental protocol with times of LPS injections, BMP-2/ACS transplantation and sacriﬁce. (B) Experimental
grouping and related experimental examination of this study.
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in which bone formation could be observed histologically. For
immunohistochemical staining, the sections were deparafﬁnized
through xylene, rehydrated through a descending ethanol series
and washed in distilled water. Endogenous peroxidase was blocked
by incubating the sections with 0.3% hydrogen peroxide. After
washed with phosphate buffer solution (PBS) (pH 7.4), the sections
were treated with normal horse serum for 30 min and subse-
quently incubated with anti-OCN antibody (1:50, Epitomics, USA)
overnight at 4C. Then, the sections were washed with PBS and
incubated with horseradish peroxidase streptavidin conjugate for
30 min. Isotype-matched control immunoglobulin G (IgG)s and
primary antibody omission showed no background staining. The
rate of OCN-positive area was evaluated by Image-Pro Plus ver. 6.0
software in a blinded fashion (Media Cybernetics, MD, USA).
Micro-computed tomographic (mCT) scanning
The specimens harvested at days 28 and 56 were mCT scanned
(SkyScan1176, Skyscan, Belgium) for quantitative evaluation of new
bone. The resulting images were 2000  1048-pixel square images
with an aluminumecopper ﬁlter used to produce optimizedimages. Reconstructions and analyses were performed using NRe-
con reconstruction and CTAn 1.8 software, respectively. To measure
newly formed bone, a circular area of pre-deﬁned size was selected
as the region of interest (ROI) in two-dimensional images. The pixel
zone representing ossiﬁcation in the deﬁned ROI was then recon-
structed in 3D by creating a volume of interest (VOI) in the lower
and upper ranges of the threshold using grayscale units. After using
CTAn 1.8 on each reconstructed BMP ﬁle, bone volume (BV), bone
mineral density (BMD), trabecular thickness (TbTh), trabecular
number (TbN), and trabecular separation (TbSp) were obtained
using a CT-analyzer in direct 3D based on a surface-rendered vol-
ume model according to the manufacturer's instructions. In addi-
tion, total bone mineral content (BMC) was calculated by
multiplying BV and BMD.
In vitro differentiation of osteoblasts
Primary BMSCs were isolated from the bone marrow of 4-week-
old Lewis rats as previously described25. All of the cells were
cultured in Dulbecco's Modiﬁed Eagle's Medium (DMEM), supple-
mented with 10% fetal bovine serum (FBS) (Gibco, USA). The
culturedmediumwas changed every 3 days. Only BMSCs from early
Table I
List of oligonucleotides used for quantitative real-time PCR
Target gene Sequence Reference
OCN F: 50-GACCCTCTCTCTGCTCACTCTG-30
F: 50-CCGGAGTCTATTCACCACCTTA-30
NM_013414.1
Col 1A1 F: 50-GCTTGATCTGTATCTGCCACAAT-30
F: 50-GACTCCTATGACTTCTGCGTCTG-30
NM_053304.1
Runx2 F: 50-CCATAACGGTCTTCACAAATCC-30
F: 50-GCGGGACACCTACTCTCATACT-30
NM_053470.2
OPN F: 50-AGGAAGCCAGCCAAGGTAAG-30
F: 50-AACCACTGCCAGTCTCATGG-30
M99252.1
OPG F: 50-GGACGTCAGCTCTTGTGTGA-30
R: 50-GTAGTCAGGGCAAGGGACAC-30
NM_012870.2
RANKL F: 50-AGGCTGGGCCAAGATCTCTA-30
R: 50-GATAGTCCGCAGGTACGCTC-30
NM_057149.1
GAPDH F: 50-CTCAGTTGCTGAGGAGTCCC-30
R: 50-ATTCGAGAGAAGGGAGGGCT-30
NM_017008.4
Abbreviations: F, forward primer; R, reverse primer.
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(200 ng/mL) and the cytokines TNF-a (50 ng/mL), IL-6 (20 ng/
mL), and IL-1b (20 ng/mL) (all from PeproTech, USA) were added to
the culture medium in the following osteoblastic differentiation
experiments.Fig. 2. The elevation of exogenous cytokines BMP-2 and the expression proﬁle of pro-inﬂa
implantation. (A) Changes in body weight observed during the experimental period, as
serum specimens were collected at days 3, 2, 0, 2, 4, 7, 10, 13, 16, and 18; changes in the
implantation during the experimental period (ANOVA test: P < 0.01 at days 0, 2, 4, and 7). (E
IFN-g, GM-CSF, TNF-a), and anti-inﬂammatory cytokines (IL-4, IL-5, IL-10, IL-13) at days 0
operated rats (ANOVA test: P < 0.01). Data shown are means ± 95% CI (n ¼ 10 per time p
the sham-operated group).Alkaline phosphatase (ALP) staining, Alizarin red staining, and ALP
activity measurement
Prior to staining, the BMSCs were washed with PBS and were
ﬁxed in 4% paraformaldehyde for 30 min. For ALP staining, the cells
were stained with naphthol AS-BI alkaline solution for 45 min to
visualize ALPase activity. For Alizarin red staining, the cells were
stained with 40 mM Alizarin red S (Sigma, USA) solution (pH 4.1)
for 10 min to visualize matrix calcium deposition. For quantitative
measurement of ALP activity, the BMSCs were exposed to BMP-2
and pro-inﬂammatory cytokines at the indicated concentrations
and times. The cells were lysed, and cellular ALPase activity was
measured using an alkaline phosphatase detection kit (Nanjing
Jiancheng Bioengineering Institute, China). The amount of ALP in
the cells was normalized against the total protein content.RNA extraction and quantitative real-time polymerase chain
reaction (PCR) analysis
Total RNAwas isolated from bone tissue and BMSCs using Trizol
reagent (Invitrogen, USA) according to the manufacturer's protocol.
Two micrograms of total RNA were used for reverse transcription,mmatory cytokines and anti-inﬂammatory cytokines in blood serum after BMP-2/ACS
displayed by days 32 after BMP-2/ACS implantation (ANOVA test). (BeD) The blood
serum levels of TNF-a (B), IL-6 (C), and IL-1b (D) after LPS injections and BMP-2/ACS
) Fold changes of BMP-2, pro-inﬂammatory cytokines (IL-1a, IL-1b, IL-2, IL-6, IL-12p70,
and days 4 after implantation of BMP-2/ACS, compared with the serum from sham-
oint in the LPS-injected group and the saline-injected group, n ¼ 5 per time point in
R.-L. Huang et al. / Osteoarthritis and Cartilage 22 (2014) 1186e11961190and the product was then used for real-time PCR. The quantiﬁcation
levels of osteogenic genes were analyzed using the ABI 7500 real-
time PCR System. PCR primer pairs were selected from different
exons of the corresponding genes, as shown in Table I. All of the PCR
procedures were performed with initial denaturation at 95C for
30 s, followed by 40 cycles at 95C for 5 s, 60C for 34 s, a melting
curve at 95C for 15 s, and 60C for 60 s continuously.
Statistical analysis
Every experiment was performed at least in triplicate technical
replicates. All of the data are presented as mean ± 95% conﬁdence
intervals (CI) from at least three independent assays. One-way
analysis of variance (ANOVA) test and Tukey's post-test multiple
comparison tests were used to determine signiﬁcance between
experimental groups [Fig. 2(AeE)]. Student's t test was used to
determine signiﬁcance between two groups [Figs. 4(CeH), 5(B, D,
EeL), 6(CeG)]. P values <0.05 were considered statistically signif-
icant, IBM SPSS statistics ver. 20 was used for statistical analysis.
Results
LPS injections and BMP-2/ACS implantation induced signiﬁcant
elevation of TNF-a, IL-6 and IL-1b in blood serum
In the clinic, trauma, possible contamination, degradation of ACS,
and underlying diseases can induce an acute or chronic inﬂamma-
tory environment before BMP-2/ACS implantation. With these fac-
tors in mind, we supplemented LPS injections with BMP-2/ACSFig. 3. LPS injections and BMP-2/ACS implantation triggered signiﬁcant inﬂammatory inﬁltra
H&E stained specimens from LPS-injected rats and saline-injected rats, harvested at 3 days
images of implants and the left panels showed the large images of implants (100 magniﬁimplantation to mimic the exaggerated inﬂammatory environment
under clinical conditions (Fig. 1). Before the study, we measured the
body weights of the rats to assess whether LPS injections had any
inﬂuence on rat growth during the experimental period. Initially, we
observed a small ﬂuctuation in body weight after LPS injections,
which stabilized after a few days [Fig. 2(A)]. To evaluate the charac-
teristics of inﬂammatory environment after LPS injections and BMP-
2/ACS implantation, we analyzed the expression proﬁle of inﬂam-
matory cytokines in serum. Firstly, we used the serum specimens
from days 0 (the day before BMP-2/ACS implantation) and 4 (4 days
after BMP-2/ACS implantation) to detect and compare the level of
BMP-2 and inﬂammatory cytokines. As shown in Fig. 2(E), compared
with the serum from sham-operated rats, regardless of whether in-
jection of LPS or saline, there was nearly a 200-fold rise of BMP-2
level in serum 4 days after BMP-2/ACS implantation, that indicate a
high-concentration and persistent elevation of exogenous BMP-2
after BMP-2/ACS implantation. Most importantly, the cytokines
analysis showed multiple elevations of the pro-inﬂammatory and
anti-inﬂammatory cytokines after LPS injections and BMP-2/ACS
implantation, but TNF-a, IL-6, and IL-1b were the most extensively
elevated inﬂammatorycytokines [Fig. 2(E)]. Then,we chose the three
mostelevatedpro-inﬂammatorycytokines (TNF-a, IL-6, and IL-1b) to
perform a time course study of these cytokines. Compared with the
sham-operative group, these cytokines in the LPS-injected group
began to increase1dayafter LPS injectionandreached themaximum
levels on days 2 to days 7 after implantation [Fig. 2(BeD)].Moreover,
these cytokines in the saline-injected groupwere also elevated after
BMP-2/ACS implantation, but signiﬁcantly lower in expression level
and shorter in maintaining time than those in LPS-injected rats.tion surrounding ASC implants. Microscopic ﬁndings showed the inﬂammatory zone in
(A) and 8 days after BMP-2/ACS implantation (B). The right panels showed the merged
cation) (n ¼ 6 per time point and group).
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inﬂammatory inﬁltration surrounding ASC implants
To estimate the inﬂammatory response after LPS injections and
BMP-2/ACS implantation, we examined the inﬂammatory zones
surrounding the BMP-2/ACS implants. As shown in Fig. 3(A and B),
from days 3 to days 8 after implantation, the volume of the im-
plants shrank, and the inﬂammatory cells inﬁltration area extended
from the outer sphere to entire implant. The data indicate that LPS
injections and BMP-2/ACS implantation provoked an exaggerated
inﬂammatory response surrounding ACS implants.
Inﬂammatory environment decreased BMP-2/ACS-induced bone
mass
To explore the effects of an exaggerated inﬂammatory envi-
ronment on BMP-2/ACS-induced osteogenesis in vivo, we analyzed
the ectopically formed bone nodules. The representative gross view
and 3D reconstructive images demonstrated that the mineral
nodules from the LPS-injected rats were obviously smaller than
those from the saline-injected rats [Fig. 4(A and B)]. Histologically,
newly induced woven bone was observed in the implants at 8
weeks from LPS and saline-injected rats, however, the TbTh, TbN,
and TbSp seem different in H&E and VG staining images [Fig. 4(B)].
To quantitatively evaluate these differences, we analyzed the data
from mCT scanning. The values of these indicators presented in
Fig. 4(CeE), revealed that LPS injections resulted in a signiﬁcantFig. 4. Inﬂammatory environment decreased BMP-2-induced bone mass. (A) Gross view of B
at 4 weeks and 8 weeks after implantation, scale bar ¼ 1 mm. (B) Representative mCT, H&E
and saline-injected groups, scale bar ¼ 1 mm, 200 magniﬁcation. (CeH) TbTh (C), TbN (D),
mCT. Data shown are means ± 95% CI (NB, new bone; ST, soft tissue; MT, mesenchymal tissdecrease in new bone formation, compared with the saline injec-
tion. The volume and content of new bone from LPS-injected rats
showed the same tendency with these bone mass indicators shown
by consistently lower than saline-injected rats at both 4 and 8
weeks [Fig. 4(F and G)]. These results indicate that an exaggerated
inﬂammatory environment signiﬁcantly inhibited BMP-2/ACS-
induced bone formation. Furthermore, we also observed that the
BMD of the LPS-treated BMP-2/ACS implants was signiﬁcantly
lower at 4 weeks and was slightly lower at 8 weeks [Fig. 4(H)],
indicating that the exaggerated inﬂammatory environment also
activated bone resorption.
Exaggerated inﬂammatory environment changed the expression of
bone turnover markers
It has been well established that several pro-inﬂammatory cy-
tokines, including TNF-a and IL-1b, could stimulate osteoclasto-
genesis and inhibit osteoblastogenesis under pathological
conditions in vivo28e30. To further clarify the effects of exaggerated
inﬂammatory environment on BMP-2/ACS-induced bone forma-
tion, wemeasured the changes of several bone turnover markers at
4 weeks after implantation. Immunohistochemical staining of OCN
was also detected in the implants from both LPS and saline-injected
rats at 8 weeks [Fig. 5(A)]; however, the positive expression area of
OCN from LPS-injected group was smaller than that from saline-
injected group [Fig. 5(B)]. The mRNA and cytokine levels of bone
formation markers, including the bone mineralization marker OCNMP-2/ACS implant specimens from LPS-injected rats and saline-injected rats, harvested
staining, and VG staining images of BMP-2/ACS implants at 8 weeks from LPS-injected
TbSp (E), BV (F), BMC (G), and BMD (H) of the newly formed bone nodules, measured by
ue; Student's t test, n ¼ 10 per time point and group).
Fig. 5. Exaggerated inﬂammatory environment changed expression of bone turnover markers. (A) Immunohistochemical staining of OCN in BMP-2/ACS implants from LPS-injected
rats and saline-injected rats at 8 weeks. (B) Quantitation analysis of OCN expression in 200 magniﬁcation. (C) TRAP staining of osteoclasts in BMP-2/ACS implants at 8 weeks
in 400 magniﬁcation. (D) Number of TRAP-positive cells per ﬁeld of tissue in 400 magniﬁcation. (E and F) Expression of OCN as a bone formation-related marker at mRNA level in
implants and protein level in serum at 4 weeks, mRNA level normalized vs GAPDH. (G) Expression of Runx2 as a bone formation-related marker at protein level in serum at 4 weeks.
(H) Secretion of TRAcP-5b as an osteoclast-related marker in serum in serum at 4 weeks. (I) Secretion of CTX-1 as a bone resorption-related marker in serum at 4 weeks. (J and K)
Expression of RANKL (J) and OPG (K) in mRNA levels as bone resorption-related markers in implants at 4 weeks, normalized vs GAPDH. (L) RANKL/OPG ratio. Data shown are
means ± 95% CI (NB, new bone; MT, mesenchymal tissue; OC, osteoclast; Student's t test, n ¼ 10 per time point and group for tissue specimens, and n ¼ 5 per time point and group
for serum specimens).
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decreased in the mineral nodules from LPS-injected rats, but not in
those from saline-injected rats [Fig. 5(EeG)]. These results indicate
that the exaggerated inﬂammation inhibited the BMP-2-induced
osteoblastic differentiation of stem cells.
Bone resorption was mainly mediated by osteoclasts which
could be identiﬁed by TRAP positivity, to investigate the role of
exaggerated inﬂammation on osteoclastogenesis, we stained the
osteoclasts in the implants by TRAP staining and counted the TRAP-
positive cells under microscope, we found that the number of
TRAP-positive cells in regenerated bony nodules was signiﬁcantlydecreased in LPS-injected rats [Fig. 5(C and D)]. Furthermore,
another osteoclast marker in serum TRAcP-5b also decreased in
LPS-injected rats [Fig. 5(H)]. We also measured the cytokine levels
of the bone resorption marker CTX-1 in serum, and the data
showed a signiﬁcant increase in serum CTX-1 in LPS-injected rats
[Fig. 5(I)]. Furthermore, receptor activator of NF-kB ligand (RANKL),
which is a key cytokine in bone resorption, showed an increased
mRNA expression in mineral nodules from LPS-injected rats
[Fig. 5(J)]. The mRNA level of osteoprotegerin (OPG), which is a
RANKL decoy receptor, remained unchanged [Fig. 5(K)]. Thus, the
RANKL/OPG ratio was increased in LPS-injected rats [Fig. 5(L)].
Fig. 6. TNF-a and IL-1b, but not IL-6, attenuated BMP-2-induced osteoblastic differentiation of BMSCs. (A and B) BMSCs were treated with BMP-2 in the presence or absence of TNF-
a, IL-6, and IL-1b respectively, ALP staining assay of ALPase activity on day 7 (A) and Alizarin red staining assay of calcium deposition on day 21 (B). (C) BMSCs were treated with
BMP-2 in the presence or absence of TNF-a, IL-6, and IL-1b respectively in a dose-dependent experiment. Quantiﬁcation assay of ALPase activity, normalized with total protein and
compared with the saline-treated well. (D) Quantitative analysis of Alizarin red staining, compared with the saline-treated wells. (EeG) BMSCs were treated with BMP-2 in the
presence or absence of TNF-a, IL-6, and IL-1b respectively for 48 h, real-time PCR and relative quantiﬁcation of COL1A1 (E), OCN (F), and OPN (G), normalized vs GAPDH. Data shown
are means ± 95% CI (Student's t test, n ¼ 4 per group).
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Therefore, the reduction in the BMD of LPS-treated implants could
have partly been caused by osteoclast-mediated bone resorption.
TNF-a and IL-1b, but not IL-6, inhibited BMP-2-induced osteoblastic
differentiation in BMSCs
Therefore, to conﬁrm further the hypothesis that exaggerated
inﬂammation decreased BMP-2-induced osteogenesis partly
through inhibition of osteoblastogenesis, we examined the effects
of the pro-inﬂammatory cytokines TNF-a, IL-6, and IL-1b, all of
which were elevated in this inﬂammation model, on BMP-2-
induced osteoblastic differentiation of BMCSs. In this study, TNF-a
and IL-1b, but not IL-6, showed remarkable inhibitory effects on
BMP-2-induced ALP expression [Fig. 6(A)]. These ﬁndings were
further conﬁrmed by the quantiﬁcation of ALP activity, which was
characterized by dose-dependent inhibitory effects of TNF-a and IL-
1b on BMP-2-upregualted ALP activity [Fig. 6(C)]. Similarly, Alizarin
red staining and quantiﬁcation showed that TNF-a and IL-1binhibited BMP-2-induced mineralization, whereas IL-6 did not
affect BMP-2-induced mineralization [Fig. 6(BeD)]. Moreover, we
further veriﬁed these ﬁndings by quantiﬁcation of osteogenic
markers in mRNA levels, such as collagen type 1 (COL1A1), OCN,
and osteopontin (OPN). The data demonstrated that the presence of
TNF-a or IL-1b could inhibit BMP-2-induced COL1A1, OCN, and OPN
expression. In contrast, no signiﬁcant changes were observed after
IL-6 treatment [Fig. 6(EeG)]. These results showed that among the
major pro-inﬂammatory cytokines elevated in our model, TNF-a
and IL-1b inhibited BMP-2-induced osteoblastic differentiation and
mineralization of BMSCs, indicating that those cytokinesmight play
a crucial role in inﬂammation-mediated negative effects on BMP-2-
induced osteogenesis.
Discussion
Despite BMP-2's well-established functions in promoting oste-
oblast development and their widespread clinical use in promoting
localized bone growth and healing in orthopedic and maxillofacial
Fig. 7. Cartoon describing the possible mechanism for inﬂammatory environment
decreasing BMP-2/ACSeinduced ectopic bone mass. In this study, LPS injections and
BMP-2/ACS implantation trigger an exaggerated inﬂammatory environment, which
characterized by secretion of inﬂammatory cytokines and inﬁltration of inﬂammatory
cells. Then, the exaggerated inﬂammatory environment inhibits BMP-2/ACS-induced
osteoblastic differentiation of stem cells, and subsequently suppressed BMP-2/ACS-
induced bone formation. However, the exaggerated inﬂammatory environment also
activates osteoclastic-related bone resorption in this model. Taken together, the
exaggerated inﬂammatory environment decreases BMP-2/ACS-induced bone mass
through inhibition of osteoblastic-related bone formation and activation of
osteoclastic-related bone resorption.
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versies regarding the osteoinductive properties of BMP-2 in clinical
setting continues to mount7,11,12, particularly the concerns
regarding the effects of exaggerated inﬂammation on the osteoin-
ductive efﬁcacy of BMP-2 in vivo22e24. In this study, we found that
exaggerated inﬂammation, triggered by LPS injections and BMP-2/
ACS implantation, exhibited a signiﬁcant inhibitory effect on BMP-
2/ACS-induced ectopic bone formation. More importantly, we
observed that exaggerated inﬂammation may exert this inhibitory
effect through inhibition of BMP-2-induced osteoblastogenesis and
activation of osteoclastogenesis (Fig. 7).
A robust literature has described an exaggerated inﬂammatory
response after implantation of BMP-2/ACS in animal models or
clinical settings. Several major factors could be responsible for this
phenomenon. Before BMP-2/ACS implantation, trauma, possible
contamination, basic diseases, or other environmental stresses
could induce an exaggerated inﬂammatory response. Furthermore,
after BMP-2/ACS implantation, surgical trauma, degradation of
ACS31,32, even the exogenous BMP-214e16 could trigger an exag-
gerated inﬂammatory response. A pre-existing inﬂammatory
environment could change the microenvironment in the injury site
and the biological properties of stem cells that may affect the
osteoinductive efﬁcacy of BMP-233,34. With these points under
consideration, we treated rats with LPS injections before BMP-2/
ACS implantation to stimulate a pre-operative inﬂammatory envi-
ronment to mimic as much as possible the real exaggerated in-
ﬂammatory environment under clinical conditions (Fig. 1). The
elevation of pro-inﬂammatory cytokines including TNF-a, IL-6, and
IL-1b in serum and the inﬁltration of inﬂammatory cells around
BMP-2/ACS implants conﬁrmed that an exaggerated inﬂammatory
environment was artiﬁcially provoked after LPS injections and
BMP-2/ACS implantation. The expression proﬁle of inﬂammatory
cytokines was consistent with several previous studies18,19,35,
particularly with a clinical case study that found that TNF-a and IL-
6 were impressively elevated in the seroma ﬂuid obtained from a
BMP-2/ACS implant site9. Meanwhile, we also conﬁrmed signiﬁcant
elevation of exogenous BMP-2 after BMP-2/ACS implantation,
suggesting that the exaggerated inﬂammatory response does not
affect the release of rhBMP-2 from ACS.
The effects of inﬂammation on bone regeneration are complex
and biphasic. It is highly conceivable that a very ﬁne balance be-
tween the inﬂammation and osteogenesis processes is key to the
ﬁnal results of bone regeneration. Numerous studies have proved
that clinical use of BMP-2/ACS is safe and productive2e5, however,
emerging concerns regarding the safety and osteoinductive efﬁcacy
of BMP-2 in vivo have continued to mount recently11,36e38. In this
study, the changes in bone mass parameters showed signiﬁcant
inhibition of bone formation in LPS-injected rats. We hypothesize
that this inconsistency might have resulted from the exaggerated
inﬂammatory response. To conﬁrm this hypothesis further, we
detected several bone formation markers in mRNA, cytokine and
protein levels in serum and bone nodules. The results showed that
Runx2, OCN, and OPN were signiﬁcantly decreased, indicating the
exaggerated inﬂammatory environment may inhibit the differen-
tiation process of osteoblasts in vivo.
TNF-a has been reported to inhibit BMP-2-induced osteoblastic
differentiation by stimulation of several signaling pathways in os-
teoblasts26,27. However, the in vivo inﬂammatory environment,
characterized by elevation of a series of pro-inﬂammatory cyto-
kines such as TNF-a, IL-1b and IL-6, is more complex than the
in vitro inﬂammation model triggered by inﬂammatory cytokines
or agonist treatment, and limited research has been focused on the
effects of IL-6 and IL-1b on BMP-2-induced osteoblastic differen-
tiation. To understand more clearly the inhibitory effects of exag-
gerated inﬂammation on BMP-2-induced bone formation, we co-treated BMSCs with BMP-2 and pro-inﬂammatory cytokines. Our
data showed that TNF-a and IL-1b could inhibit BMP-2-induced
osteoblastic differentiation, while IL-6 showed no inﬂuence on
this capacity. Combined with our previous study which showed LPS
inhibited BMP-2-induced osteoblastic differentiation in vivo25,
these data suggest that the exaggerated inﬂammatory environment
decreases BMP-2/ACS-induced bone formation through the inhi-
bition of BMP-2-induced osteoblastic differentiation.
More interestingly, we also observed a remarkably decreased
BMD and increased osteoclastogenic activity in the implants from
LPS-injected rats. The data indicate that the decreased bone mass
might also have resulted in bone resorption. Two major factors
could have been involved in the bone resorption in this model. On
the one hand, pro-inﬂammatory cytokines, such as TNF-a, IL-1b, IL-
6, IL-11, and IL-17, can directly stimulate osteoclastogenesis and
then result in osteoclastic bone resorption28,39,40. In particular, TNF-
a and IL-1b can synergize with RANKL to potentiate bone
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consistent with our results representing elevation of the RANKL/
OPG ratio, but it was complementally conﬁrmed by the up-regu-
lated osteoclast number and TRAcP-5b level. On the other hand,
high concentrations of exogenous BMP-2 also have been proved to
induce bone resorption through activation of osteoclastogenesis in
clinical cases and experimental observations10,44e46. The data
suggest that an exaggerated inﬂammatory environment also
decreased BMP-2/ACS-induced bone mass through activation of
bone resorption by increasing the number or activity of osteoclasts.
Conclusion
Collectively, our study demonstrated that the exaggerated in-
ﬂammatory environment may decrease BMP-2-induced bone mass
by suppressing osteoblastogenesis-mediated bone formation and
activating osteoclastogenesis-mediated bone resorption. These
data might therefore provide an explanation for the transient and
low osteoinductive capacity of BMP-2 in clinical cases. Thus, in the
future, suppression of the inﬂammatory response should be care-
fully considered around the period of BMP-2/ACS implantation to
enhance the osteoinductive efﬁcacy of BMP-2.
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